Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 12-Month High – Here’s What Happened

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) reached a new 52-week high on Wednesday . The company traded as high as $16.73 and last traded at $16.66, with a volume of 1825247 shares changing hands. The stock had previously closed at $16.11.

Analyst Ratings Changes

Several equities analysts recently issued reports on AMRX shares. UBS Group began coverage on Amneal Pharmaceuticals in a research report on Friday, April 17th. They set a “buy” rating and a $19.00 price target on the stock. Barclays boosted their price objective on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, May 20th. Truist Financial increased their price objective on Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Zacks Research cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. Finally, Weiss Ratings downgraded shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, May 26th. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, Amneal Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $15.80.

Amneal Pharmaceuticals Price Performance

The company has a market capitalization of $5.31 billion, a P/E ratio of 43.84 and a beta of 1.30. The company has a 50 day moving average of $13.56 and a 200-day moving average of $13.29.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.27 earnings per share (EPS) for the quarter. The company had revenue of $722.52 million for the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%. Research analysts predict that Amneal Pharmaceuticals, Inc. will post 0.92 EPS for the current fiscal year.

Insider Activity

In other news, Director Deborah M. Autor sold 34,819 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $12.94, for a total transaction of $450,557.86. Following the transaction, the director directly owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. The trade was a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 17.30% of the company’s stock.

Institutional Trading of Amneal Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AMRX. Kemnay Advisory Services Inc. bought a new stake in Amneal Pharmaceuticals in the fourth quarter valued at $26,000. Federated Hermes Inc. raised its holdings in Amneal Pharmaceuticals by 1,680.6% in the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after purchasing an additional 2,168 shares in the last quarter. Comerica Bank raised its holdings in Amneal Pharmaceuticals by 186.7% in the 3rd quarter. Comerica Bank now owns 3,005 shares of the company’s stock worth $30,000 after purchasing an additional 1,957 shares in the last quarter. Spire Wealth Management lifted its position in shares of Amneal Pharmaceuticals by 66.6% in the 4th quarter. Spire Wealth Management now owns 2,558 shares of the company’s stock worth $32,000 after purchasing an additional 1,023 shares during the period. Finally, Transamerica Financial Advisors LLC lifted its position in shares of Amneal Pharmaceuticals by 541.9% in the 4th quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock worth $37,000 after purchasing an additional 2,460 shares during the period. Hedge funds and other institutional investors own 31.82% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.